BioGaia AB (BIOG B):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioGaia AB (BIOG B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10130
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. BioGaia’s products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults, and controls digestive problems such as colic, regurgitation, diarrhea and constipation. The company’ sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.

BioGaia AB (BIOG B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10
BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioGaia AB, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13
BioGaia Enters into Agreement with Abbott Laboratories De Chile 14
BioGaia Enters into Agreement with Laboratorios Silanes 15
BioGaia Enters Into Distribution Agreement With Ache Labs 16
BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 17
BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 18
BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 19
Licensing Agreements 20
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 20
BioGaia Enters Into Licensing Agreement With Nestle 21
BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22
BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23
Equity Offering 24
Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 24
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 26
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 28
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 29
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 30
Acquisition 31
BioGaia Acquires Additional 26% Stake in MetaboGen for USD1.4 Million 31
BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32
BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33
BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34
BioGaia Acquires Remaining 50% Stake In TwoPac 35
BioGaia AB – Key Competitors 36
BioGaia AB – Key Employees 37
BioGaia AB – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Strategy And Business Planning 40
Apr 24, 2018: BioGaia: New initiative in the fight against antibiotic resistance 40
Jun 21, 2017: BioGaia sets up subsidiary for the development of probiotic drugs 41
Financial Announcements 42
Oct 24, 2018: BioGaia – Interim management statement 1 January – 30 September 2018 42
Aug 17, 2018: BioGaia – Interim report January 1 – June 30, 2018 43
Apr 25, 2018: BioGaia – Interim management statement 1 January – 31 March 2018 44
Feb 08, 2018: BioGaia – Year-end report 2017 45
Oct 25, 2017: BioGaia–Interim management statement January 1–September 30, 2017 46
Aug 18, 2017: BioGaia Interim report 1 January – 30 June 2017 47
May 03, 2017: BioGaia – Interim management statement 1 January – 31 March 2017 48
Feb 10, 2017: BioGaia – Year-end report 2016 49
Corporate Communications 50
May 23, 2018: BioGaia: Management Changes 50
Product News 51
Nov 07, 2017: BioGaia’s probiotic shown to promote growth and prevent recurrent diarrhea 51
Oct 08, 2018: MetaboGen reaches development goal – first product ready for safety study 52
Mar 23, 2018: Dr Reddy’s launches BioGaia Protectis drops in India 53
Mar 19, 2018: BioGaia’s oral health probiotic launched in several European markets as GUM PerioBalance 54
Feb 12, 2018: BioGaia Protectis with vitamin D now available at Apoteket, Apotek Hjartat and Apotea 55
Jan 11, 2018: BioGaia Protectis with vitamin D soon in the Swedish market 56
Other Significant Developments 57
Apr 24, 2018: New Initiative in the Fight Against Antibiotic Resistance 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
BioGaia AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioGaia AB, Deals By Therapy Area, 2012 to YTD 2018 9
BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10
BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13
BioGaia Enters into Agreement with Abbott Laboratories De Chile 14
BioGaia Enters into Agreement with Laboratorios Silanes 15
BioGaia Enters Into Distribution Agreement With Ache Labs 16
BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 17
BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 18
BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 19
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 20
BioGaia Enters Into Licensing Agreement With Nestle 21
BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22
BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23
Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 24
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 26
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 28
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 29
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 30
BioGaia Acquires Additional 26% Stake in MetaboGen for USD1.4 Million 31
BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32
BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33
BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34
BioGaia Acquires Remaining 50% Stake In TwoPac 35
BioGaia AB, Key Competitors 36
BioGaia AB, Key Employees 37
BioGaia AB, Other Locations 38
BioGaia AB, Subsidiaries 38

List of Figures
BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioGaia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioGaia AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[BioGaia AB (BIOG B):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cognoptix Inc-医療機器分野:企業M&A・提携分析
    Summary Cognoptix Inc (Cognoptix), formerly Neuroptix Corp, is a medical device company that develops and offers eye-scanning test for the early detection and diagnosis of Alzheimer’s disease. The company develops technology which is used to detect the presence of Alzheimer’s related beta amyloid pr …
  • Atmos Energy Corporation (ATO)-石油・ガス分野:企業M&A・提携分析
    Summary Atmos Energy Corporation (Atmos Energy) is a natural gas distribution utility. It operates in the regulated natural gas distribution and pipeline businesses, and other nonregulated natural gas businesses. The company delivers natural gas through regulated sales and transportation arrangement …
  • ams AG (AMS):企業の財務・戦略的SWOT分析
    Summary ams AG (ams), formerly austriamicrosystems AG is a technology company that manufactures and markets semiconductor products. The company's products comprise audio systems, environmental sensors, light sensors, smart light management, spectral sensing, CMOS imaging sensors, medical imaging and …
  • Oxford Biodynamics Plc-製薬・医療分野:企業M&A・提携分析
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a biotechnology company that discovers and develops biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, …
  • Rowan Companies plc:企業の戦略・SWOT・財務分析
    Rowan Companies plc - Strategy, SWOT and Corporate Finance Report Summary Rowan Companies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • KP Energy Ltd (539686):電力:M&Aディール及び事業提携情報
    Summary KP Energy Ltd (KP Energy) is an alternative energy company that offers power and wind energy solutions. The company provides services such as turnkey solutions, BOT basis services, land acquisition, project development, cost studies, site identification, capacity installations, engineer, pro …
  • Handelsbanken Great Britain
    Handelsbanken Great Britain - Strategy, SWOT and Corporate Finance Report Summary Handelsbanken Great Britain - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Societe Nationale Industrielle et Miniere:企業の戦略・SWOT・財務情報
    Societe Nationale Industrielle et Miniere - Strategy, SWOT and Corporate Finance Report Summary Societe Nationale Industrielle et Miniere - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Fonterra Co-operative Group Ltd:戦略・SWOT・企業財務分析
    Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Oil Refineries Ltd (ORL):企業の財務・戦略的SWOT分析
    Oil Refineries Ltd (ORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Almirall S.A.:企業の戦略・SWOT・財務分析
    Almirall S.A. - Strategy, SWOT and Corporate Finance Report Summary Almirall S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Origin Energy Ltd (ORG)-エネルギー分野:企業M&A・提携分析
    Summary Origin Energy Limited (Origin Energy) is an integrated energy company. It generates, supplies and distributes electricity; explores and develops natural gas reserves; and produces and sells gas. The company generates electricity from natural-gas fired, coal-fired, wind, solar, pumped water s …
  • Defense Commissary Agency:企業の戦略的SWOT分析
    Defense Commissary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Power Climber Wind:企業の戦略的SWOT分析
    Power Climber Wind - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Ophthotech Corp (OPHT):製薬・医療:M&Aディール及び事業提携情報
    Summary Ophthotech Corp (Ophthotech) is a biopharmaceutical company that offers novel therapeutics to treat diseases of the back of the eye for age-related macular degeneration. The company’s products include Zimura, an anti-complemente is a central component of the complement cascade that is suppos …
  • Domino’s Pizza, Inc.:企業の戦略・SWOT・財務分析
    Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report Summary Domino's Pizza, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Universal Health Services Inc (UHS):企業の財務・戦略的SWOT分析
    Universal Health Services Inc (UHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CoImmune Inc (ARGS):企業の財務・戦略的SWOT分析
    Summary CoImmune Inc(CoImmune) formerly known as Argos Therapeutics Inc, is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of infectious diseases and cancer. The company develops a pipeline of products based on its proprietary Arcelis technology platfo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆